New biologics in the treatment of rare glomerular diseases of childhood

Paolo Cravedi, Andrea Angeletti, Giuseppe Remuzzi

Research output: Contribution to journalReview article

Abstract

Minimal change disease and focal segmental glomerulosclerosis are rare but important causes of end-stage kidney disease in children. Though their pathogenesis is still unclear, evidence of immune abnormalities provided the background for the use of immunosuppressive drugs, such as corticosteroids, calcineurin inhibitors, antiproliferative and alkylating agents. Unfortunately, these treatments fail to achieve a sustained remission in a significant portion of patients and are burdened by significant toxicities. Recent developments of new biologics, including anti-CD20 monoclonal antibodies rituximab and ofatumumab, offered the opportunity to selectively target immune cell subsets or activation pathways, leading to more effective and safer hypothesis-driven treatments.

Original languageEnglish
Pages (from-to)27-33
Number of pages7
JournalCurrent Opinion in Pharmacology
Volume33
DOIs
Publication statusPublished - Apr 1 2017

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'New biologics in the treatment of rare glomerular diseases of childhood'. Together they form a unique fingerprint.

  • Cite this